A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma — OLYMPIA-2

Follicular Lymphoma (FL) Clinical Trial

Official title:
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)

Status Recruiting

Clinical Trial Summary

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma in Part 2, as well as participants with lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"), in Part 1. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study. The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug - How much study drug is in your blood at different times - Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) - The impact from the study drug on your quality-of-life and ability to complete routine daily activities

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06097364
Study type	Interventional
Source	Regeneron Pharmaceuticals
Contact	Clinical Trials Administrator
Phone	844-734-6643
Email	clinicaltrials@regeneron.com
Status	Recruiting
Phase	Phase 3
Start date	November 14, 2023
Completion date	January 24, 2030

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06043011` - Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Recruiting	`NCT05409066` - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma	Phase 3
Terminated	`NCT03571828` - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma	Phase 1
Terminated	`NCT02914938` - A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma	Phase 1
Recruiting	`NCT05888493` - A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma	Phase 3
Active, not recruiting	`NCT04049513` - ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)	Phase 1
Recruiting	`NCT03869619` - REal World Data in LYmphoma and Survival in Adults
Active, not recruiting	`NCT04830137` - A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1
Recruiting	`NCT03547115` - A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML	Phase 1
Not yet recruiting	`NCT04767308` - Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies	Early Phase 1
Terminated	`NCT03768505` - Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)	Phase 2
Recruiting	`NCT03265158` - Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0	N/A
Enrolling by invitation	`NCT04488354` - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T	Phase 1
Recruiting	`NCT05720052` - A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT06191744` - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma	Phase 3
Active, not recruiting	`NCT02362035` - ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT06091254` - A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma	Phase 3
Enrolling by invitation	`NCT02875548` - A Study to Assess the Long-term Safety of Tazemetostat	Phase 1/Phase 2
Active, not recruiting	`NCT04450069` - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies	Phase 1
Terminated	`NCT04745832` - Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)	Phase 3